PT - JOURNAL ARTICLE AU - Donna Grace Karp AU - Kenneth Danh AU - David Seftel AU - Peter V. Robinson AU - Cheng-ting Tsai TI - A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots AID - 10.1101/2020.05.29.20116004 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.29.20116004 4099 - http://medrxiv.org/content/early/2020/06/03/2020.05.29.20116004.short 4100 - http://medrxiv.org/content/early/2020/06/03/2020.05.29.20116004.full AB - Accurate surveillance of coronavirus disease 2019 (COVID-19) incidence requires large-scale testing of the population. Current testing methods require in-person collection of biospecimens by a healthcare worker, limiting access of individuals who do not have access to testing facilities while placing both patients and healthcare workers at risk of exposure to infection. We report the development and validation of a at-home finger-prick dried blood spot collection kit and an analysis method. We demonstrated 100% sensitivity and specificity using at-home collected specimens across the US. Such methods may facilitate the conduct of unbiased serosurveys within hard to reach populations and help reduce the sample collection burden of serological testing on both health care systems and individuals alike.Competing Interest StatementK.D., D.G.K., D.S., P.V.R. and C.T.T are employees of Enable Biosciences.Clinical TrialThis study is not a clinical trial and does not involve intervention to the study participants.Funding StatementThe study is funded in part by NIH SBIR 2R44DK110005-02 and 2RAI141118-02 to Enable Biosciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided informed consents under the Western IRB approved IRB protocol #20180015 to Enable Biosciences.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll reagents and data from this study will be made available upon reasonable request from the corresponding author.